カテゴリー： 世界, 医療/バイオ, Grand View Research

血液腫瘍検査の世界市場2023-2030：市場規模、シェア、動向分析

【英語タイトル】Hemato Oncology Testing Market Size, Share & Trends Analysis Report By Product (Assay Kits & Reagents, Services), By Cancer Type (Leukemia, Lymphoma), By Technology, By End-use, By Region, And Segment Forecasts, 2023 - 2030

Grand View Researchが出版した調査資料（GRV23SEP062）・商品コード：GRV23SEP062
・発行会社（調査会社）：Grand View Research
・発行日：2023年8月
・ページ数：150
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：臨床診断
◆販売価格オプション（消費税別）
Single UserUSD5,950 ⇒換算￥904,400見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算￥1,056,400見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算￥1,360,400見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

血液腫瘍検査市場の成長と動向
Grand View Research, Inc.の最新レポートによると、世界の血液腫瘍学検査市場規模は、2023年から2030年にかけて年平均成長率12.54%で成長し、2030年には80億米ドルに達する見込みです。骨髄腫とリンパ腫の有病率の上昇が、予測期間中の市場成長を促進する見込みです。米国癌協会によると、2022年に米国で新たに診断される多発性骨髄腫の患者数は約34,470人で、そのうち女性は15,370人、男性は19,100人です。また、2022 年には、女性 5,550 人、男性 7,090 人を含む合計 12,640 人が死亡すると予測されています。したがって、これらの疾患の有病率の増加は、血液腫瘍学検査製品の使用量を増加させると予想されます。

同市場は、顕著な成長と技術革新の傾向にあります。技術の進歩や癌の分子メカニズムの理解が進むにつれて、血液悪性腫瘍や固形癌を診断・モニタリングするための専門的な検査に対する需要が高まっています。この市場では、遺伝子プロファイルに基づいて個々の患者に合った的確な標的治療を行う個別化医療へのシフトが見られます。このため、コンパニオン診断検査が開発され、次世代シーケンシング（NGS）やその他の高度な分子技術が血液腫瘍検査に統合されています。プレシジョン・メディシンが普及し、新しい技術が診断能力をさらに高めるにつれて、市場は拡大し続けると予想されます。

大手企業や研究機関の連携が進むとともに、技術的に優れた血液腫瘍学的検査を創出するための学術・研究機関の研究活動も増加しており、市場成長の原動力となることが期待されます。例えば、サノフィは2022年3月、Blackstone Life Sciences と提携し、3億2891万米ドルを投資して多発性骨髄腫の治療を前進させました。これにより、多発性骨髄腫の検査と治療がさらに加速するでしょう。

製品上市数の増加も市場成長を促進する主な要因です。例えば、2021年7月、サーモフィッシャーサイエンティフィックは、Ion Torrent Oncomine免疫範囲アッセイの新しいコレクションを追加することにより、血液腫瘍学NGSポートフォリオを拡張しました。この発売により、同社は研究者が血液がんをより正確に分析できるよう支援することを目的としています。

さらに、精密医療の開発における研究コミュニティの関与の高まりが、市場の成長をさらに加速しています。例えば、シンシナティ大学がんセンターは2021年9月、急性骨髄性白血病（AML）患者を対象とした個別化医療試験「Beat AML」を開始しました。同大学はこの試験のために複数の研究機関と協力しています。このように、個別化治療への注目の高まりは、血液がんやそのサブタイプに関する認知度の大幅な向上に寄与しており、市場の成長を促進しています。

血液がん検査市場レポートハイライト

- がんの種類別では、ホジキンリンパ腫および非ホジキンリンパ腫の有病率の増加により、リンパ腫が2022年に46.66%の最大売上シェアで市場を支配しました。

- 製品別では、がん罹患率の増加、テーラーメード医薬品など様々な治療オプションに対する意識の高まりにより、サービス分野が2022年に58.23%の最大売上シェアを占めました。

- 技術別では、PCR分野が2022年に31.08%の最大売上シェアで市場を支配し、その使いやすさ、正確さ、手頃な価格、効率性、製品の上市数や承認数の増加により、急激な成長を目の当たりにしました。

- 最終用途別では、病院分野が予測期間中に12.8%と最も速いCAGRを記録すると予測されています。また、血液腫瘍診断検査へのアクセスのしやすさ、診断検査を実施し疾患を監視する医療専門家の存在により、2022年には75.07%の最大の売上シェアを占めました。

- 北米は、多発性骨髄腫の有病率の上昇、意識の高まり、および血液腫瘍診断のための技術的に高度な製品の発売により、予測期間中に13.6%という最も速いCAGRを記録する見込みです。

第1章．調査手法＆範囲
第2章．エグゼクティブサマリー
第3章．血液腫瘍検査市場：市場変動・動向・範囲
第4章．血液腫瘍検査市場：がん種別予測＆動向分析
第5章．血液腫瘍検査市場：製品別予測＆動向分析
第6章．血液腫瘍検査市場：技術別予測＆動向分析
第7章．血液腫瘍検査市場：用途別予測＆動向分析
第8章．血液腫瘍検査市場：地域別予測＆動向分析
第9章．血液腫瘍検査市場：競争状況
第10章．アナリスト見解

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

Table Of Contents

Chapter 1. Methodology And Scope
1.1. Market Segmentation And Scope
1.1.1. Segment Definitions
1.1.1.1. Product Segment
1.1.1.2. Technique Segment
1.1.1.3. Type Segment
1.1.1.4. Application Segment
1.1.1.5. Scale Of Operations Segment
1.2. Information Procurement
1.2.1. Market Formulation & Data Visualization
1.2.2. Data Validation & Publishing
1.3. Research Assumptions
1.4. Research Methodology
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.4.5. Details Of Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.7.1.1. Approach 1: Commodity Flow Approach
1.8. List Of Secondary Sources
1.9. Global Market: CAGR Calculation
1.10. Objectives
1.10.1. Objective 1
1.10.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Cancer Type And Product Snapshot
2.3. Technology And End-Use Snapshot
2.4. Competitive Landscape Snapshot
Chapter 3. Hemato Oncology Testing Market Variables And Trends
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Impact Analysis
3.2.1.1. Increasing Prevalence Of Lymphoma & Myeloma
3.2.1.2. Growing Demand For Personalized Therapy
3.2.1.3. Availability Of Advanced Molecular Techniques For Hemato-Oncology Diagnostics
3.2.1.4. Increasing Drug-Diagnostics Co-Development
3.2.2. Market Restraint Impact Analysis
3.2.2.1. Unfavorable Reimbursement Scenario.
3.3. Impact Of The Covid-19 Pandemic
3.4. Industry Analysis Tools
3.4.1. Porter’s Analysis
3.4.2. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
Chapter 4. Hemato Oncology Testing Market: Cancer Type Estimates & Trend Analysis
4.1. Cancer Type Movement Analysis & Market Share, 2022 & 2030
4.2. Hemato Oncology Testing Market Estimates & Forecast, By Cancer Type (USD Million)
4.3. Leukemia
4.3.1. Global Leukemia Market Estimates And Forecasts, 2018 – 2030 (USD Million)
4.3.2. Acute Myeloid Leukemia (AML)
4.3.2.1. Global Acute Myeloid Leukemia (AML) Market Estimates And Forecasts, 2018 – 2030 (USD Million)
4.3.3. Acute Lymphocytic Leukemia (ALL)
4.3.3.1. Global Acute Lymphocytic Leukemia (ALL) Market Estimates And Forecasts, 2018 – 2030 (USD Million)
4.3.4. Chronic Lymphocytic Leukemia
4.3.4.1. Global Chronic Lymphocytic Leukemia Market Estimates And Forecasts, 2018 – 2030 (USD Million)
4.3.5. Chronic Myeloid Leukemia
4.3.5.1. Global Chronic Myeloid Leukemia Market Estimates And Forecasts, 2018 – 2030 (USD Million)
4.4. Lymphoma
4.4.1. Global Lymphoma Market Estimates And Forecasts, 2018 – 2030 (USD Million)
4.4.2. Non-Hodgkin Lymphoma
4.4.2.1. Global Non-Hodgkin Lymphoma Market Estimates And Forecasts, 2018 – 2030 (USD Million)
4.4.3. Hodgkin Lymphoma
4.4.3.1. Global Hodgkin Lymphoma Market Estimates And Forecasts, 2018 – 2030 (USD Million)
4.5. Myeloproliferative Neoplasms
4.5.1. Global Myeloproliferative Neoplasms Market Estimates And Forecasts, 2018 – 2030 (USD Million)
4.5.2. Polycythemia Vera (PV)
4.5.2.1. Global Polycythemia Vera (PV) Market Estimates And Forecasts, 2018 – 2030 (USD Million)
4.5.3. Essential Thrombocythemia (ET)
4.5.3.1. Global Essential Thrombocythemia (ET) Market Estimates And Forecasts, 2018 – 2030 (USD Million)
4.5.4. Myelofibrosis (MF)
4.5.4.1. Global Myelofibrosis (MF) Market Estimates And Forecasts, 2018 – 2030 (USD Million)
4.6. Others Cancers
4.6.1. Global Others Cancers Market Estimates And Forecasts, 2018 – 2030 (USD Million)
Chapter 5. Hemato Oncology Testing Market: Product Estimates & Trend Analysis
5.1. Product Movement Analysis & Market Share, 2022 & 2030
5.2. Hemato Oncology Testing Market Estimates & Forecast, By Product (USD Million)
5.3. Assay Kits And Reagents
5.3.1. Global Assay Kits And Reagents Market Estimates And Forecasts, 2018 – 2030 (USD Million)
5.4. Services
5.4.1. Global Services Market Estimates And Forecasts, 2018 – 2030 (USD Million)
Chapter 6. Hemato Oncology Testing Market: Technology Estimates & Trend Analysis
6.1. Technology Movement Analysis & Market Share, 2022 & 2030
6.2. Hemato Oncology Testing Market Estimates & Forecasts, By Technology (USD Million)
6.3. PCR
6.3.1. Global PCR Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.3.2. Real-Time qPCR
6.3.2.1. Global Real-Time qPCR Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.3.3. Digital PCR
6.3.3.1. Global Digital PCR Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.4. Ihc
6.4.1. Global IHC Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.5. Ngs
6.5.1. Global NGS Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.6. Cytogenetics
6.6.1. Global Cytogenetics Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.7. Other Technologies
6.7.1. Global Other Technologies Market Estimates And Forecasts, 2018 – 2030 (USD Million)
Chapter 7. Hemato Oncology Testing Market: Application Estimates & Trend Analysis
7.1. Application Movement Analysis & Market Share, 2022 & 2030
7.2. Hemato Oncology Testing Market Estimates & Forecast, By Application (USD Million)
7.3. Hospitals
7.3.1. Global Hospitals Market Estimates And Forecasts, 2018 – 2030 (USD Million)
7.4. Academic & Research Institutes
7.4.1. Global Academic & Research Institutes Market Estimates And Forecasts, 2018 – 2030 (USD Million)
7.5. Others
7.5.1. Global Others Market Estimates And Forecasts, 2018 – 2030 (USD Million)
Chapter 8. Hemato Oncology Testing Market: Regional Estimates And Trend Analysis
8.1. Hemato Oncology Testing Market: Regional Outlook
8.2. North America
8.2.1. North America Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.2.2. U.S.
8.2.2.1. Key Country Dynamics
8.2.2.2. Competitive Scenario
8.2.2.3. Regulatory Framework
8.2.2.4. U.S. Hemato Oncology Testing Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.2.3. Canada
8.2.3.1. Key Country Dynamics
8.2.3.2. Competitive Scenario
8.2.3.3. Regulatory Framework
8.2.3.4. Canada Hemato Oncology Testing Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.3. Europe
8.3.1. Europe Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.3.2. Germany
8.3.2.1. Key Country Dynamics
8.3.2.2. Competitive Scenario
8.3.2.3. Regulatory Framework
8.3.2.4. Germany Hemato Oncology Testing Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.3.3. UK
8.3.3.1. Key Country Dynamics
8.3.3.2. Competitive Scenario
8.3.3.3. Regulatory Framework
8.3.3.4. UK Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.3.4. France
8.3.4.1. Key Country Dynamics
8.3.4.2. Competitive Scenario
8.3.4.3. Regulatory Framework
8.3.4.4. France Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.3.5. Italy
8.3.5.1. Key Country Dynamics
8.3.5.2. Competitive Scenario
8.3.5.3. Regulatory Framework
8.3.5.4. Italy Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.3.6. Spain
8.3.6.1. Key Country Dynamics
8.3.6.2. Competitive Scenario
8.3.6.3. Regulatory Framework
8.3.6.4. Spain Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.3.7. Russia
8.3.7.1. Key Country Dynamics
8.3.7.2. Competitive Scenario
8.3.7.3. Regulatory Framework
8.3.7.4. Russia Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.3.8. Denmark
8.3.8.1. Key Country Dynamics
8.3.8.2. Competitive Scenario
8.3.8.3. Regulatory Framework
8.3.8.4. Denmark Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.3.9. Sweden
8.3.9.1. Key Country Dynamics
8.3.9.2. Competitive Scenario
8.3.9.3. Regulatory Framework
8.3.9.4. Sweden Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.3.10. Norway
8.3.10.1. Key Country Dynamics
8.3.10.2. Competitive Scenario
8.3.10.3. Regulatory Framework
8.3.10.4. Norway Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.4. Asia Pacific
8.4.1. Asia Pacific Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.4.2. Japan
8.4.2.1. Key Country Dynamics
8.4.2.2. Competitive Scenario
8.4.2.3. Regulatory Framework
8.4.2.4. Japan Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.4.3. China
8.4.3.1. Key Country Dynamics
8.4.3.2. Competitive Scenario
8.4.3.3. Regulatory Framework
8.4.3.4. China Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.4.4. India
8.4.4.1. Key Country Dynamics
8.4.4.2. Competitive Scenario
8.4.4.3. Regulatory Framework
8.4.4.4. India Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.4.5. South Korea
8.4.5.1. Key Country Dynamics
8.4.5.2. Competitive Scenario
8.4.5.3. Regulatory Framework
8.4.5.4. South Korea Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.4.6. Singapore
8.4.6.1. Key Country Dynamics
8.4.6.2. Competitive Scenario
8.4.6.3. Regulatory Framework
8.4.6.4. Singapore Asia Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.4.7. Australia
8.4.7.1. Key Country Dynamics
8.4.7.2. Competitive Scenario
8.4.7.3. Regulatory Framework
8.4.7.4. Australia Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.4.8. Thailand
8.4.8.1. Key Country Dynamics
8.4.8.2. Competitive Scenario
8.4.8.3. Regulatory Framework
8.4.8.4. Thailand Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.5. Latin America
8.5.1. Latin America Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.5.2. Brazil
8.5.2.1. Key Country Dynamics
8.5.2.2. Competitive Scenario
8.5.2.3. Regulatory Framework
8.5.2.4. Brazil Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.5.3. Mexico
8.5.3.1. Key Country Dynamics
8.5.3.2. Competitive Scenario
8.5.3.3. Regulatory Framework
8.5.3.4. Mexico Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.5.4. Argentina
8.5.4.1. Key Country Dynamics
8.5.4.2. Competitive Scenario
8.5.4.3. Regulatory Framework
8.5.4.4. Argentina Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.6. MEA
8.6.1. MEA Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.6.2. South Africa
8.6.2.1. Key Country Dynamics
8.6.2.2. Competitive Scenario
8.6.2.3. Regulatory Framework
8.6.2.4. South Africa Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.6.3. Saudi Arabia
8.6.3.1. Key Country Dynamics
8.6.3.2. Competitive Scenario
8.6.3.3. Regulatory Framework
8.6.3.4. Saudi Arabia Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.6.4. UAE
8.6.4.1. Key Country Dynamics
8.6.4.2. Competitive Scenario
8.6.4.3. Regulatory Framework
8.6.4.4. UAE Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
8.6.5. Kuwait
8.6.5.1. Key Country Dynamics
8.6.5.2. Competitive Scenario
8.6.5.3. Regulatory Framework
8.6.5.4. Kuwait Hemato Oncology Testing Market Estimates And Forecasts, 2018 – 2030 (USD Million)
Chapter 9. Hemato Oncology Testing Market: Competitive Landscape
9.1. Participant Categorization
9.1.1. Amoy Diagnostics Co. Ltd
9.1.1.1. Overview
9.1.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.1.3. Product Benchmarking
9.1.1.4. Strategic Initiatives
9.1.2. EntroGen
9.1.2.1. Overview
9.1.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.2.3. Product Benchmarking
9.1.2.4. Strategic Initiatives
9.1.3. Cepheid
9.1.3.1. Overview
9.1.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.3.3. Product Benchmarking
9.1.3.4. Strategic Initiatives
9.1.4. ASURAGEN, INC
9.1.4.1. Overview
9.1.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.4.3. Product Benchmarking
9.1.4.4. Strategic Initiatives
9.1.5. ArcherDX, Inc.
9.1.5.1. Overview
9.1.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.5.3. Product Benchmarking
9.1.5.4. Strategic Initiatives
9.1.6. Invivoscribe, Inc.
9.1.6.1. Overview
9.1.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.6.3. Product Benchmarking
9.1.6.4. Strategic Initiatives
9.1.7. Adaptive Biotechnologies
9.1.7.1. Overview
9.1.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.7.3. Product Benchmarking
9.1.7.4. Strategic Initiatives
9.1.8. Abbott
9.1.8.1. Overview
9.1.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.8.3. Product Benchmarking
9.1.8.4. Strategic Initiatives
9.1.9. ARUP Laboratories
9.1.9.1. Overview
9.1.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.9.3. Product Benchmarking
9.1.9.4. Strategic Initiatives
9.1.10. Illumina, Inc.
9.1.10.1. Overview
9.1.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.10.3. Product Benchmarking
9.1.10.4. Strategic Initiatives
9.1.11. Bio-Rad Laboratories, Inc.
9.1.11.1. Overview
9.1.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
9.1.11.3. Product Benchmarking
9.1.11.4. Strategic Initiatives
9.2. Participant’s Overview
9.3. Financial Performance
9.4. Product Benchmarking
9.5. Company Market Share Analysis, 2022
9.6. Strategy Mapping
9.6.1. Expansion
9.6.2. Acquisition
9.6.3. Product/Service Launch
9.6.4. Others
Chapter 10. Analyst View

List of Tables

Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 List of key emerging companies/product disruptors/innovators
Table 4 North America hemato oncology testing market, by country, 2018 - 2030 (USD Million)
Table 5 North America hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 6 North America hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 7 North America hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 8 North America hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 9 U.S. hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 10 U.S. hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 11 U.S. hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 12 U.S. hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 13 Canada hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 14 Canada hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 15 Canada hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 16 Canada hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 17 Europe hemato oncology testing market, by country, 2018 - 2030 (USD Million)
Table 18 Europe hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 19 Europe hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 20 Europe hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 21 Europe hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 22 U.K. hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 23 U.K. hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 24 U.K. hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 25 U.K. hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 26 Germany hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 27 Germany hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 28 Germany hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 29 Germany hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 30 France hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 31 France hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 32 France hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 33 France hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 34 Italy hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 35 Italy hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 36 Italy hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 37 Italy hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 38 Spain hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 39 Spain hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 40 Spain hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 41 Spain hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 42 Sweden hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 43 Sweden hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 44 Sweden hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 45 Sweden hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 46 Russia hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 47 Russia hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 48 Russia hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 49 Russia hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 50 Denmark hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 51 Denmark hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 52 Denmark hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 53 Denmark hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 54 Norway hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 55 Norway hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 56 Norway hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 57 Norway hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 58 Asia Pacific hemato oncology testing market, by country, 2018 - 2030 (USD Million)
Table 59 Asia Pacific hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 60 Asia Pacific hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 61 Asia Pacific hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 62 Asia Pacific hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 63 Japan hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 64 Japan hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 65 Japan hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 66 Japan hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 67 China hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 68 China hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 69 China hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 70 China hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 71 India hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 72 India hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 73 India hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 74 India hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 75 South Korea hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 76 South Korea hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 77 South Korea hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 78 South Korea hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 79 Australia hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 80 Australia hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 81 Australia hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 82 Australia hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 83 Singapore hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 84 Singapore hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 85 Singapore hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 86 Singapore hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 87 Thailand hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 88 Thailand hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 89 Thailand hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 90 Thailand hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 91 Latin America hemato oncology testing market, by country, 2018 - 2030 (USD Million)
Table 92 Latin America hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 93 Latin America hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 94 Latin America hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 95 Latin America hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 96 Brazil hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 97 Brazil hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 98 Brazil hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 99 Brazil hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 100 Mexico hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 101 Mexico hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 102 Mexico hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 103 Mexico hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 104 Argentina hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 105 Argentina hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 106 Argentina hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 107 Argentina hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 108 MEA hemato oncology testing market, by country, 2018 - 2030 (USD Million)
Table 109 MEA hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 110 MEA hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 111 MEA hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 112 MEA hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 113 South Africa hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 114 South Africa hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 115 South Africa hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 116 South Africa hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 117 Saudi Arabia hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 118 Saudi Arabia hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 119 Saudi Arabia hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 120 Saudi Arabia hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 121 UAE hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 122 UAE hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 123 UAE hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 124 UAE hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)
Table 125 Kuwait hemato oncology testing market, by cancer type, 2018 - 2030 (USD Million)
Table 126 Kuwait hemato oncology testing market, by product, 2018 - 2030 (USD Million)
Table 127 Kuwait hemato oncology testing market, by technology, 2018 - 2030 (USD Million)
Table 128 Kuwait hemato oncology testing market, By End-use, 2018 - 2030 (USD Million)

★調査レポート[血液腫瘍検査の世界市場2023-2030：市場規模、シェア、動向分析] (コード：GRV23SEP062)販売に関する免責事項を必ずご確認ください。
★調査レポート[血液腫瘍検査の世界市場2023-2030：市場規模、シェア、動向分析]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 血液腫瘍検査の世界市場2023-2030：市場規模、シェア、動向分析
  • 着床前遺伝子検査（PGT）の世界市場2023-2030：市場規模、シェア、動向分析
  • 着床前遺伝子検査（PGT）の世界市場2023-2030：市場規模、シェア、動向分析
  • DNA診断の世界市場2023-2030：市場規模、シェア、動向分析
  • DNA診断の世界市場2023-2030：市場規模、シェア、動向分析
  • 血液検査の世界市場2023-2030：市場規模、シェア、動向分析
  • 血液検査の世界市場2023-2030：市場規模、シェア、動向分析
  • 産業用微生物試験サービスの世界市場2023-2030：市場規模、シェア、動向分析
  • 産業用微生物試験サービスの世界市場2023-2030：市場規模、シェア、動向分析
  • HPV検査＆パップテストの世界市場2023-2030：市場規模、シェア、動向分析

    • ◆H&Iグローバルリサーチのお客様（例）◆